Hydrocortisone

證據等級: L5

預測適應症: 10 個

Hydrocortisone: From Corticosteroid-Responsive Inflammatory Conditions to Alopecia Areata

One-Sentence Summary

Hydrocortisone is a glucocorticoid receptor agonist with long-established use in adrenocortical insufficiency and inflammatory/allergic skin conditions; detailed original-indication and regulatory data are not present in this evidence pack, and the product is currently not marketed in New Zealand. The TxGNN model predicts it may be effective for Alopecia Areata, with 4 clinical trials and 20 publications currently supporting this direction, including one completed head-to-head Phase 3 RCT against a higher-potency steroid.

Quick Overview

Item	Content
Original Indication	Not available from regulatory data on file (drug is not currently licensed in New Zealand); generally known as a corticosteroid for adrenocortical insufficiency and inflammatory/allergic conditions
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L2 (1 completed Phase 3 RCT directly comparing hydrocortisone to clobetasol)
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, hydrocortisone is a glucocorticoid receptor agonist; when applied topically or intralesionally, it suppresses perifollicular T-cell infiltration and inflammatory mediator release, helping restore the immune privilege of the hair follicle. This is a well-characterized mechanism of action for corticosteroids in autoimmune/inflammatory dermatoses.

Alopecia areata is understood to be a T-cell-mediated autoimmune disease targeting hair follicles, and topical corticosteroids — including hydrocortisone — have been used in clinical practice for decades as a treatment option, particularly in children and mild disease. This is therefore not a novel biological hypothesis so much as a confirmation, by the model, of an existing low-potency treatment option within a drug class (topical corticosteroids) already used off-label/on-label for this condition in various markets.

Importantly, the single head-to-head RCT identified (NCT01453686, published as PMID 24226568) directly compared hydrocortisone 1% cream to clobetasol propionate 0.05% cream in children with alopecia areata, and reported that hydrocortisone was less effective than the higher-potency steroid. This positions hydrocortisone as a conservative, lower-potency option — appropriate for mild disease or pediatric patients where a lower-potency steroid is preferred — rather than a primary therapy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453686	Phase 3	Completed	41	RCT directly comparing topical hydrocortisone 1% cream vs clobetasol propionate 0.05% cream in children with alopecia areata; hydrocortisone is the standard-of-comparison (lower-potency) arm (relevance grade A)
NCT00484679	Phase 2	Completed	18	Evaluated adrenal (HPA-axis) suppression from intralesional triamcinolone (not hydrocortisone itself) in alopecia areata patients; a safety, not efficacy, endpoint for a related corticosteroid (relevance grade B)
NCT04343560	N/A	Completed	380	Observational study of abnormal steroid metabolome and bone density/quality in patients with mild autonomous cortisol secretion; not focused on alopecia areata treatment, likely a keyword-based mismatch (relevance grade C)
NCT06551818	N/A	Not Yet Recruiting	72	Planned 4-arm dose-response study of hair growth products for androgenic (not areata) alopecia; not yet recruiting, no data available (relevance grade B)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24226568	2014	RCT	JAMA Dermatology	Randomized trial in children: clobetasol propionate 0.05% vs hydrocortisone 1% for alopecia areata (published results of NCT01453686)
36718837	2023	Systematic Review/Meta-analysis	Journal of Cosmetic Dermatology	Reviews fractional laser (alone/combination) therapy for alopecia areata; corticosteroids referenced as existing comparator treatments
38501938	2024	Clinical Study (retrospective)	Clinical and Experimental Dermatology	Efficacy/safety of topical corticosteroid under occlusion for severe alopecia areata (including alopecia totalis/universalis) in children
28516731	2017	Review	JEADV	Reviews hypothalamic-pituitary-adrenal axis activity and cortisol production in alopecia areata patients
29227263	2017	Review	Georgian Medical News	Reviews adaptive hormonal (cortisol/insulin) regulatory mechanisms in alopecia areata
13368875	1956	Case Series	Medical Times	Early clinical series treating alopecia areata, partialis, and totalis with cortisone, hydrocortisone, prednisone and prednisolone
15692503	2005	Case Report	J Am Acad Dermatol	4 cases of congenital alopecia areata treated with topical steroids and minoxidil
13610145	1958	Case Series	Der Hautarzt	Hair regrowth in alopecia areata/maligna following intracutaneous hydrocortisone injection
5989830	1966	Case Series	Vestnik Dermatologii i Venerologii	Treatment of alopecia areata and total alopecia with intracutaneous hydrocortisone injections
14158891	1963	Case Series	Actas Dermo-Sifiliograficas	Treatment of alopecia areata with intradermal hydrocortisone injections

New Zealand Market Information

Hydrocortisone currently has no product authorizations on file and is not marketed in New Zealand (0 licenses). No dosage form or approved-indication data is available to report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted use is mechanistically well grounded and reflects existing, decades-old clinical practice (low-potency topical/intralesional corticosteroid for alopecia areata) rather than a novel repurposing hypothesis. However, the only direct RCT evidence shows hydrocortisone is less effective than a higher-potency comparator (clobetasol), and the drug currently has no market authorization or approved indication in New Zealand, so guardrails — rather than an unrestricted "Go" — are warranted.

To proceed, the following is needed:

TFDA/NZ package insert warnings, contraindications, and drug interaction data (currently a Blocking data gap — DG001)
Confirmed mechanism of action documentation (currently a High-severity data gap — DG002)
Clarification of regulatory pathway, since the product is not currently licensed/marketed in New Zealand (0 authorizations)
A defined clinical positioning (e.g., mild/pediatric alopecia areata as a lower-potency option) relative to higher-potency alternatives already supported by RCT evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.